Role of nitric oxide in the haemodynamic effects of growth hormone

Growth Hormone and IGF Research

Volumn 8, Issue SUPPL. 2, 1998, Pages 163-165

  Boger R H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; GROWTH HORMONE DEFICIENCY; HEMODYNAMICS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0032461814     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1096-6374(98)80044-0     Document Type: Article

References (8)

1. Förstermann U, Closs EI, Pollack JS et al. Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131.
2. Moncada S, Higgs EA. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
3. Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson AH. The nature of the endothelium-derived vascular relaxant factor. Nature 1984; 308: 645-647.
4. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30: 535-560.
5. - excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin Exp Pharmacol Physiol 1996; 23: 11-15.
6. Bode-Böger SM, Böger RH, Alfke H et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996; 93: 85-90.
7. Wolf A, Zalpour C, Theilmeier G et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29: 479-485.
8. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655.